Evgen Pharma (EVG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.000p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 7.10
  • 52 Week Low: 2.85
  • Currency: UK Pounds
  • Shares Issued: 274.89m
  • Volume: 0
  • RiskGrade: 304

Evgen Pharma Overview

Evgen is a clinical stage drug development company focused on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation.

1 Day Chart (02-02-2023)

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a -780.0%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a 24.5
Pr/Book 1.3  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Evgen Pharma Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-18 n/a (3.03) (3.23)p n/a n/a n/a n/a 0.0%
31-Mar-19 n/a (3.12) (2.70)p n/a n/a n/a n/a 0.0%
31-Mar-20 n/a (3.17) (2.07)p n/a n/a n/a n/a 0.0%
31-Mar-21 0.19 (3.21) (1.82)p n/a n/a n/a n/a 0.0%
31-Mar-22 n/a (3.17) (0.99)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Evgen Pharma Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-23 0.50 (3.90) (1.20)p n/a n/a n/a n/a 0.0%
31-Mar-24 5.00 (1.60) (0.20)p n/a n/a n/a n/a 0.0%

Copyright © 2023 FactSet Research Systems Inc. All rights reserved.

Evgen Pharma Company Announcements

Clinical trial update 25-Jan-2023 07:00 RNS
Grant of Options - Director/PDMR Shareholding 14-Dec-2022 17:08 RNS
Half-year Report 08-Dec-2022 07:00 RNS

Latest Evgen Pharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Evgen Pharma Market Data

Currency UK Pounds
Share Price 4.00p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 7.10
52 Week Low 2.85
Volume 0
Shares Issued 274.89m
RiskGrade 304

Evgen Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
11.24% below the market average11.24% below the market average11.24% below the market average11.24% below the market average11.24% below the market average
51.72% above the sector average51.72% above the sector average51.72% above the sector average51.72% above the sector average51.72% above the sector average
Price Trend
7.78% above the market average7.78% above the market average7.78% above the market average7.78% above the market average7.78% above the market average
45.16% above the sector average45.16% above the sector average45.16% above the sector average45.16% above the sector average45.16% above the sector average
Income Not Available
Growth Not Available

Evgen Pharma Dividends

No dividends found

Trades for 02-Feb-2023

Time Volume / Share Price
16:29 22,232 @ 4.50p
14:54 15,000 @ 4.37p
14:51 10,000 @ 4.37p
13:53 126,951 @ 4.46p
13:30 21,929 @ 4.46p

Evgen Pharma Key Personnel

CFO Richard Moulson
CEO Huw Jones

Top of Page